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Stability can be defined as the capacity of a drug substance or drug product to sus-
tain its identity, strength, quality, and purity throughout the retest or expiration period
(1). Stability testing of an active substance or finished product provides evidence of the
quality of a drug substance or drug product to remain acceptable up to the stated period
under storage conditions stated on the label. The International Conference on Harmoni-
zation (ICH) guidelines Q1A (R2) require the use of a validated stability-indicating assay
method (SIAM) for stability testing of a drug substance or product (2). It also empha-
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A simple, sensitive and precise RP-HPLC-DAD method
was developed and validated for the determination of ol-
mesartan medoxomil (AT-II receptor blocker) in the pre-
sence of its degradation products. Olmesartan medoxo-
mil and all the degradation products were resolved on a
C18 column with the mobile phase composed of metha-
nol, acetonitrile and water (60:15:25, V/V/V, pH 3.5 by
orthophosphoric acid) at 260 nm using a photodiode ar-
ray detector. The method was linear over the concentra-
tion range of 1–18 mg mL–1 and precise with RSD < 1 %
in intra- and inter-day study. Excellent recoveries of 99.3
± 0.9 to 100.8 ± 1.2 % proved the accuracy of the method.
Developed method was specific, as indicated by chroma-
tographic resolution > 2.0 for each peak and sensitive with
LOD 0.03 mg mL-1 and LOQ 0.1 mg mL–1. The method was
used to study the drug degradation behavior under forc-
ed conditions. Four degradation products (DP-I, II, III, IV)
were formed during the degradation study in 0.1 mol L–1
HCl whereas only DP-I, II and III were formed in water,
0.01 mol L–1 NaOH and 3 % H2O2. No significant ther-
mal or photolytic degradation was observed in solid drug.
The method was applied successfully for the assay of ol-
mesartan medoxomil in the tablet dosage form.
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sizes the conduct of a forced degradation study on the drug substance to generate infor-
mation on degradation products that can form under the influence of hydrolytic, oxida-
tive, thermal or photolytic degradation conditions.
Olmesartan medoxomil (OLM) (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4- (1-hy-
droxy-1-methylethyl)-2-propyl-1-4-[2-(tetrazol-5-yl)-phenyl]phenylmethyl imidazo-5-
-carboxylate) (Fig. 1a) is a prodrug and rapidly hydrolyzes in plasma during absorption
to form its active metabolite olmesartan (Fig. 1b) (3–5). It is a selective AT1 subtype an-
giotensin II receptor blocker (6, 7), which was recently approved by the US-FDA (8) to
treat patients with hypertension. This reduces blood pressure by causing vasodilation
and reducing peripheral resistance (9). OLM is also reported to be effective in animal
models of atherosclerosis, liver disorders and diabetic nephropathy (10).
Methods of analyses of olmesartan medoxomil in biological fluids such as human
plasma and urine by LC-MS and LC-MS-MS were reported previously (11–13). Use of
capillary zone electrophoresis (CZE) for the determination of OLM in pharmaceutical
dosage form has also been reported (14). No stability indicating assay of OLM in bulk
and solid dosage form could be traced in the literature. However, the method that iden-
tified the main degradation products obtained during short-time storage using the hy-
phenated techniques has been reported (15). This method described the storage of tab-
lets at 40 °C/75 % RH for 6 months and identification of the degradation product by
complementary use of the HPLC hyphenated techniques (LC-IR, LC-NMR and LC-MS)
without isolation or purification processes.
In the present study, we aimed to develop and validate a stability indicating RP-
-HPLC-DAD assay method that allowed resolution, detection and quantitation of olme-
sartan medoxomil in the presence of degradation products obtained during the forced
conditions in bulk substance and tablet dosage form.
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Fig. 1. Chemical structure of olmesartan medoxomil and its free carboxylic acid form olmesartan.
EXPERIMENTAL
Chemicals and reagents
Olmesartan medoxomil was kindly provided as a gift a sample by Torrent Pharma-
ceutical Ltd. (India) with 99.94 % purity. Tablet dosage form of olmesartan medoxomil
(Olmecip, Cipla Ltd. India, 20 mg) was purchased from a local pharmacy. HPLC grade
methanol and acetonitrile were purchased from S.D. Fine Chemical, India. Hydrochloric
acid, sodium hydroxide pellets, hydrogen peroxide solution, and orthophosphoric acid
were also purchased from S.D. Fine Chemical and were of analytical grade. Water for
RP-HPLC was prepared by triple distillation in a glass still and filtered through a nylon
0.45 mm membrane filter (Gelman Laboratory, India).
Instruments
The Shimadzu (Japan) LC system (LC-2010c HT) was equipped with a diode array
detector (SPD-M20A), auto sampler (SIL-10ADvp) and column oven CTO-10A(C) vp.
Chromatographic separations were performed using the Phenomenex (Torrance, USA)
C18 column (250 mm ´ 4.6 mm id, 5 mm particle size) at 35 °C column oven temperature
and analyzed by LC solution software Shimad. For photolytic degradation, the UV cabi-
net producing short wavelength (254 nm) produced by Acemas Technocracy Prt. Ltd, In-
dia was used. High precision water bath and hot air oven (Narang Scientific Works, In-
dia) capable of controlling the temperature within ± 1 and ± 2 °C, respectively, were
used for the hydrolytic and thermal degradation studies.
Preparation of standard solutions
A stock solution of olmesartan medoxomil was prepared by dissolving the drug in
methanol to get a concentration of 1.0 mg mL–1. Fresh stock solution was prepared every
day during the experiment. Working solution containing 100 mg mL–1 was prepared from
this stock solution as well as seven calibration standards (1–18 mg mL–1) and quality con-
trol samples (4, 10 and 14 mg mL–1) by diluting appropriate aliquots of standard solu-
tions.
Preparation of sample solution
Twenty tablets were weighed, transferred to a clean, dry mortar and well ground.
Powder equivalent to 50 mg drug was then transferred to a 100-mL volumetric flask
containing 50 mL methanol. The flask was attached to a rotary shaker for 10 min to dis-
perse the material completely. The mixture was then sonicated for 20 min and centri-
fuged at 3,000 rpm for 5 min. An aliquot of supernatant solution was diluted appropri-
ately to give a solution of 500 mg mL–1 and 10 mL of this solution was used for forced
degradation studies.
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Forced degradation studies
Forced degradation of drug substances and drug products was carried out under
acid/neutral/basic hydrolytic, oxidative, thermolytic, and photolytic stress conditions.
For hydrolytic and oxidative degradation, drug solutions were prepared with a concen-
tration of 500 mg mL–1. After degradation, aliquots were diluted with methanol to achieve
a concentration of 10 mg mL–1. Methanol (60 %, V/V) was used for drug solubilization in
acidic, neutral and oxidative media.
Hydrolytic degradation studies were carried out under acid (0.1 mol L–1 HCl, pH
1.03), neutral (water, pH 7.12), and basic (0.01 mol L–1 NaOH, pH 12.05) conditions at
60 °C as well as at room temperature over 12 to 48 h. Oxidative degradation was carried
out in a 3 % H2O2 solution at room temperature over 48 h.
Thermal and photo degradation of drug substances and drug products was carried
out in the solid state. For thermal degradation, the drug was spread in a borosilicate
glass Petri dish and placed in the hot-air oven maintained at 60 °C for 10 days. Also,
photolytic studies were carried out by exposing a thin layer of the solid drug in a Petri
dish in the UV chamber for 10 days during which time the total light exposure equaled
to 1.2 ´ 106 lx h. After degradation, stock solutions were prepared by dissolving the sam-
ples in methanol to achieve a concentration of 1 mg mL–1. From these solutions, aliquots
were diluted with methanol to get the final concentration of 10 mg mL–1 of OLM. Sam-
ples were withdrawn initially, subsequently at prefixed time intervals and stored at 2–8 °C
until analysis for all forced conditions.
Method development
Detection wavelength for the HPLC study was selected as 260 nm after recording
the UV spectrum from 190 to 400 nm of the drug and representative sample from each
forced condition. The maximum area and peak selectivity of OLM was observed at this
wavelength. The chromatographic conditions were optimized for resolution of the peak
of the drug and degradation products under each forced condition by varying the statio-
nary phase, proportion of methanol/acetonitrile/water in the mobile phase and the flow
rate using representative samples from each forced condition. Several trials using vari-
ous proportions of methanol and water as mobile phase were carried out. However, to
attain the selective resolution of OLM and its degradation products, acetonitrile was in-
troduced as the third solvent; apparent pH 3.5 was adjusted by orthophosphoric acid.
Subsequently, a mixture of different stress conditions was used to optimize the chroma-
tographic conditions for resolving OLM and all the degradation products in a single run.
An appropriate blank was injected before the analysis of all forced samples. Such an op-
timized method was then used to study the forced degradation behavior of OLM and
was also applied in the stability indicating assay of OLM tablets.
Validation of the method
The optimized method was validated in accordance with the ICH guidelines (16).
Linearity was determined by analyzing, in triplicate, standard drug solutions of concen-
trations 1, 2, 4, 6, 10, 14 and 18 mg mL–1 using 20 mL of the injection volume. For intra-
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-day precision, three quality control drug concentrations (4, 10 and 14 mg mL–1) were an-
alyzed seven times on the same day whereas the same drug concentrations were analyzed
on three different days for inter-day precision. Accuracy/recovery was evaluated by
spiking the mixture of degradation samples with three known drug concentrations and
calculating the percent recovery from the differences between the peak areas obtained
for concentrated and diluted solutions. Signal-to-noise ratios were employed to estimate
limits of detection (3:1) and limits of quantitation (10:1). The specificity of a method is its
suitability for analysis of a substance in the presence of potential impurities. Specificity
of the method was established through the study of the resolution (Rs) of OLM samples.
Overall selectivity was established through determination of drug purity and Rs peak
each time. Reproducibility of the method was established through separate studies on a
mixture of degradation samples by different persons on the same chromatographic sys-
tem as well as on different chromatographic systems in different laboratories on differ-
ent days by another analyst. Various system suitability parameters were also evaluated
on a mixture sample on six different days using freshly prepared mobile phase each time.
RESULTS AND DISCUSSION
Method development and optimization
The peak of pure OLM obtained using 50 % methanol and 50 % acetonitrile (V/V)
suggested to employ 70 % methanol and 30 % water (V/V), pH 3.5 adjusted with ortho-
phosphoric acid, as the mobile phase. Forced degradation samples were then analyzed
using the same mobile phase flowing at a rate of 1.0 mL min–1 on a C18 column employ-
ing DAD detection. The method resolved the drug and degradation products under neu-
tral, basic and oxidative conditions, but it could not resolve the cluster of peaks obser-
ved under acidic conditions. To separate the degradation products formed under acidic
conditions, acetonitrile was introduced in the mobile phase and all other variables were
kept the same. However, degradation products still remained unresolved under acidic
conditions. The alteration in the stationary phase from C18 to C8 and the flow rate of the
mobile phase did not furnish promising results either. Many compositions of different
mobile phase strength were tried and, finally, mobile phase composed of methanol, ace-
tonitrile and water (60:15:25, V/V/V) pH 3.5 adjusted with orthophosphoric acid, at a
flow rate of 1.0 mL min–1 on a C18 column, was used. This mobile phase could opti-
mally resolve the OLM and all the degradation products formed under different condi-
tions in the mixture sample in a single run (Fig. 2a). The relative retention time (tR) of
each peak of the degradation product with respect to olmesartan medoxomil is given in
Table I.
Validation of the method
Linearity. – Peak area and concentrations were subjected to the least square linear re-
gression analysis to calculate the calibration equations and correlation coefficients. The
calibration plot for OLM assay was linear over the calibration range 1–18 mg mL–1, and
the regression coefficient, slope and intercept were 0.998, 541214 ± 253.1 and 340.9 ± 6.2,
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respectively. These results demonstrate an excellent correlation between the peak area
and analyte concentration.
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Fig. 2. HPLC chromatograms showing resolution of olmesartan medoxomil and degradation prod-
ucts in: a) mixture of forced degradation samples in a single run, b) 0.1 mol L–1 HCl at 60 °C after 24
h, c) 0.01 mol L–1 NaOH at RT after 4 h, d) water at 60 °C after 48 h, e) 3 % H2O2 at RT after 48 h.
Limits of detection and quantification. – LOD was 0.03 mg mL–1 for OLM at a signal-
-to-noise ratio of 3:1 and the limit of quantification was determined as 0.1 mg mL–1 for
OLM at a signal-to-noise ratio of 10:1.
Precision. – Intra-day precision was expressed throught relative standard deviation
of seven repeated assays of samples at three concentration levels. Inter-day precision was
determined by analyzing the same set of samples on five different days. RSD in the pre-
cision study for the OLM assay was less than 1.0 % and confirmed that the method was
highly precise. Results of the precision study for OLM by the proposed RP-HPLC-DAD
method are given in Table II.
Recovery. – Standard addition method was used to examine the recovery of the RP-
-HPLC-DAD method (17). Recovery of OLM from bulk drug samples ranged from 99.3 ±
0.9 to 100.7 ± 1.0 % and that from tablet dosage forms ranged from 99.5 ± 0.8 to 100.8 ±
1.2 % (Table III).
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Table I. Relative retention time, peak purity data and system suitability parameters of olmesartan
medoxomil and its degradation products
Parameter
Peak
DP-I DP-II DP-III DP-IV OLM
Relative retention time (tR)a 0.740 0.809 0.932 1.154 1.000
Peak purity index 0.789 1.000 0.999 0.999 1.000
Purity threshold 0.842 0.998 0.883 0.974 0.999
Asymmetry (As) 1.11 1.28 1.23 1.32 1.06
Tailing factor (T) 1.044 – – – 1.058
Chromatographic resolution (Rs) 1.91 1.24 1.99 2.05 1.16
Capacity factor (k’) 4.93 5.48 6.47 7.02 8.26
Selectivity (á)b 1.11 1.18 1.08 1.17
Number of theoretical plates (N) 2725.85 3164.63 3195.41 4215.38 2688.93
a With respect to OLM.
b With respect to succeeding peak.
Table II. Precision data of the proposed RP-HPLC-DAD method
Actual conc.
(mg mL–1)
Measured concentration (mg mL–1)a
Interday Intraday
4.0 4.0 ± 0.1 3.9 ± 0.4
10.0 9.8 ± 0.3 10.2 ± 0.5
14.0 14.1 ± 0.2 13.8 ± 0.8
a Mean ± SD, n = 7.
Specificity. – There was no interference due to placebo and sample diluents and deg-
radation products. Resolution between closely eluting degradation products, i.e., between
DP-I, DP-II, and between DP-III, OLM, were greater than 2.0, illustrated the chromato-
graphic selectivity of the method.
Stability of stock solution. – During solution stability and mobile phase stability ex-
periments, RSD for the OLM assay was within 1 % for three replicates. Results of the so-
lution stability and mobile phase stability experiments confirmed that standard soluti-
ons and solutions in the mobile phase were stable for up to 48 h during the OLM assay.
Forced degradation
During optimization of the hydrolytic degradation process, drug samples were ini-
tially placed in 0.1 mol L–1 HCl, 0.1 mol L–1 NaOH and in water at 60 °C. However, after
24 and 48 h, the OLM sample in HCl and water showed 31 and 12 % degradation, re-
spectively, while OLM in 0.1 mol L–1 NaOH was completely degraded. Thus, we deci-
ded to carry out degradation at room temperature for the 0.1 mol L–1 NaOH sample. The
compound was completely degraded to DP-I instantly at room temperature. When NaOH
concentration was lowered to 0.01 mol L–1, the sample containing OLM was 90 % de-
graded at room temperature after 4 h.
Degradation pattern under all forced conditions showed the presence of DP-I, which
is the major degradation product of OLM formed during every degradation study. As il-
lustrated in Fig. 2b for acidic hydrolysis all the degradation products (DP-I, II, III, IV)
were observed in reasonable amounts. The OLM was degraded after 24 h at 60 °C in 0.1
mol L–1 HCl; here there was more DP-II than in other stress condition samples. For hy-
drolysis in basic medium, 0.1 mol L–1 NaOH, almost all the drug had degraded at room
temperature; however, 0.01 mol L–1 NaOH at room temperature was appropriate for sig-
nificant degradation. Three degradation products (DP-I, DP-II and DP-III) were present
in these forced samples, DP-I being the major one (Fig. 2c). Degradation in neutral hyd-
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Table III. Recovery for bulk drug substance and drug product
Conc. of drug taken
(mg mL–1)






10.0 5.0 14.9 ± 0.2 99.6 ± 0.8
10.0 10.0 19.9 ± 0.4 99.3 ± 0.9
10.0 15.0 25.1 ± 0.3 100.7 ± 1.0
Drug product
10.0 5.0 15.0 ± 0.5 100.8 ± 1.2
10.0 10.0 20.0 ± 0.3 100.3 ± 0.6
10.0 15.0 24.9 ± 0.2 99.5 ± 0.8
Mean ± SD, n = 3.
rolytic medium at 60 °C (Fig. 2d) occurred at a slower rate than under other hydrolytic
conditions. Exposure to light and dark did not exhibit any significant difference in the
degradation pattern under hydrolytic conditions. Results proved that the degradation of
OLM was more pronounced under basic hydrolytic condition than under acidic and ne-
utral conditions.
OLM degradation was 12 % under oxidative conditions (3 % H2O2) at room temper-
ature for 48 h. Oxidative degradation produced DP-I, II and III, but DP-I and II were
formed in minor amounts (Fig. 2e). No degradation was seen in solid drug kept at 60 °C
for 10 days and no degradation was observed upon exposure to light intensity of 1.2 ´
106 lx h either. Summary of the data for all forced degradations is given in Table IV.
Peak purity test suggested that the OLM peak as well as the peaks of OLM degrada-
tion products were pure for all the forced samples analyzed (Table I). No additional peak
was observed after 5 min in chromatograms obtained for the extended runtime of 25 min
in a sample study.
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Fig. 3. UV spectra of olmesartan medoxomil (OLM) and degradation products: a) DP-I, b) DP-II, c)
DP-III, d) DP-IV.
The UV spectrum of pure OLM was compared with the spectrum of the drug sub-
jected to the different forced conditions; all the spectra showed slight changes in the ab-
sorption pattern. Purity of all degradation products was confirmed by comparing their
spectra with the spectrum of OLM (Figs. 3a-d). Comparison of the spectra of two major
degradation products, DP-I and II, with the OLM spectrum (Figs. 3a and b) suggested
the absence of the ester moiety of OLM in both the DP-I and II, since the absorption maxi-
mum characteristic of the 5-methyl-2-oxo-1,3-dioxolen-4-yl-methyl group (ester moiety)
in OLM at 260 nm was not visible. Olmesartan medoxomil is an ester prodrug and easily
de-esterifies to its active metabolite olmesartan under hydrolytic conditions (4). Analo-
gously to degradation products reported to be formed in losartan tablets stored at 40 °C
and 75 % relative humidity (18), the major degradation products are DP-I, likely to be
the olmesartan free carboxylic acid form (Fig. 1b) and DP-II, the dimer of its free car-
boxylic acid form of olmesartan. The goal of determining OLM in the presence of degra-
dation products by the proposed stability indicating RP-HPLC-DAD method was suc-
cessfully achieved but the method can be also used for routine quality control of tablets.
CONCLUSIONS
The RP-HPLC-DAD method developed for quantitative analysis of olmesartan me-
doxomil in both bulk drug and pharmaceutical dosage forms is precise, accurate and
specific. Satisfactory results were obtained by validation of the method. No attempt was
made to quantify the degradation products; quantitation is possible after isolation of de-
gradation products in pure form. This method can be used for the estimation of olme-
sartan medoxomil in the presence of degradation products obtained under different for-
ced conditions.
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Table IV. Summary of forced degradation study results
Stress condition Time OLM (%) Remarks (major degradation product)
Acidic hydrolysis
(0.1 mol L–1 HCl, 60 °C)
24 h 68.7 DP-I and II
Basic hydrolysis
(0.01 mol L–1 NaOH, RT)
4 h 10.3 DP-I
Aqueous hydrolysis (60 °C) 48 h 88.1 DP-I and II
Oxidation (3% H2O2, RT) 48 h 54.3 DP-I
Thermal (60 °C) 10 days 99.4 No degradation product formed
Photo (UV 254 nm) 10 days 99.8 No major degradation product observed
OLM – olmesartan modoxomil; DP – degradation product
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S A @ E T A K
RP-HPLC-DAD metoda za odre|ivanje olmesartan medoksomila kao ~iste
supstancije i u tabletama izlo`enih razgradnji
RITESH N. SHARMA i SHYAM S. PANCHOLI
U ovom radu razvijena je i validirana jednostavna, osjetljiva i precizna RP-HPLC-
-DAD metoda za odre|ivanje olmesartan medoksomila (inhibitor AT-II receptora) u pri-
sutnosti njegovih razgradnih produkata. Olmesartan medoksomil i razgradni produkti
kromatografirani su na C18 koloni uz mobilnu fazu metanol/ acetonitril/voda (60:15:25
V/V/V; pH 3,5 pode{en ortofosfornom kiselinom) pri 260 nm uz detektor s fotodiodnim
nizom. Metoda je linearna u koncentracijskom rasponu 1–18 µg mL-1 i precizna s RSD <
1 % tijekom ispitivanja repetabilnosti i intermedijarne ponovljivosti. Povrat od 99,3 ± 0,9
do 100,8 ± 1,2 % dokazuje to~nost metode. Razvijena metoda je specifi~na na {to ukazuje
kromatografsku rezoluciju ve}u od 2,0 i osjetljiva (LOD = 0,03 µg mL-1 i LOQ = 0,1 µg mL-1).
Metoda je upotrebljena za pra}enje razgradnje olmesartan medoksomila u uvjetima po-
tencirane razgradnje. U 0,1 mol L-1 HCl detektirana su ~etiri razgradna produkta (DP-I,
II, III, IV), a u vodi, 0,01 mol L-1 NaOH i 3 % H2O2 samo DP-I, II i III. U ~vrstom agre-
gatnom stanju nije primje}ena zna~ajna termi~ka ni fotoliti~ka razgradnja ljekovite tvari.
Metoda je uspje{no primijenjena za odre|ivanje olmesartan medoksomila u tabletama.
Keywords: olmesartan medoksomil, razgradnja, teku}inska kromatografija visoke u~inkovitosti, stabilnost
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